Select your country

STADA responds to urgent need by making more medicines

  • 09/04/2020
  • Press Release
  • Information
  • March 2020 saw the highest production output in STADA’s 125-year history as the COVID-19 crisis significantly raised demand for critical medicines.

  • STADA is prioritising production of medicines that are in high demand during the current pandemic response, such as anti-infectives, immunostimulants and painkillers. Supplies of essential treatments such as cancer therapies are also a major area of focus.

  • STADA CEO Peter Goldschmidt: “I am immensely proud of how not only our STADA colleagues in production, quality assurance and logistics, but also our employees who are working from home, have stepped up around the world to keep supplying medicines to healthcare systems that desperately need them.”


Bad Vilbel, April 9, 2020
– STADA has stepped up to the challenge of satisfying rising demand for medicines and other healthcare products during the Covid-19 coronavirus response in March 2020, setting a record in terms of the company’s production output.

In March, production volumes were more than 10% above historically typical levels. This resulted in STADA internally manufacturing more than 63 million packs, comprising over 1.2 billion individual units, across its global supply-chain network during March.

“I am immensely proud of how not only our STADA colleagues in production, quality assurance and logistics, but also our employees who are working from home, have stepped up around the world to keep supplying medicines in these challenging circumstances,“ commented STADA CEO Peter Goldschmidt. “At this time, the health and safety of all our employees is foremost in our minds.”

STADA’s finished-dose production, packaging and logistics facilities are mainly located in its core markets like Germany, Russia, Serbia, the UK and Vietnam. In addition, we want to highlight and thank our more than 300 external partners who supported us to keep supplying medicines, even in these difficult times. We are putting every effort into distribution and logistics to supply and deliver our products globally, wherever our patients need them most urgently.

Working closely with its network of partners, STADA has been increasing its inventories of both raw materials and finished-dose medicines since the corona crisis started. Additional warehousing space is also helping to ensure that products are being held as close to customers as possible.

“While our entire Technical Operations team is working extremely hard to satisfy high levels of demand for our products at this time, we also take extremely seriously our duty to protect the health and wellbeing of our colleagues and their families at this time,” stressed STADA’s Chief Technical Officer, Miguel Pagan. “In addition to adhering to stringent safety guidelines and implementing supportive measures such as assisting with daily life arrangements, providing emotional support to our employees in these testing times is also a priority.”

 

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG
Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de

Additional information for capital market participants:
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de